Drugs / CAR-T Re-treatment
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03672253 | Jul 2018 → Dec 2020 | plasma cell myeloma | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T Re-treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03672253 ↗ |
| Modality | Cell therapy | “CAR-T cells targeting BCMA” NCT03672253 ↗ |
| Route | Intravenous | “by intravenous injection” NCT03672253 ↗ |